在帕金森病中治疗胃肠功能障碍的共识实践建议
Delaram Safarpour1, Natividad Stover2, David R Shprecher3
1Department of Neurology, School of Medicine, Oregon Health & Science University, Portland, OR, USA.
Parkinsonism & related disorders
|May 10, 2024
概括
胃肠道 (GI) 功能障碍在帕金森病 (PD) 中常见. 这项研究为PD患者的查,诊断和治疗肠道疾病提供了共识建议.
科学领域:
- 神经学 神经学
- 胃肠病学 胃肠病学
背景情况:
- 胃肠道 (GI) 功能障碍是帕金森病 (PD) 中普遍存在的非运动性症状.
- 在PD中,胃肠道症状可能会在运动症状出现前几年出现,严重影响患者的生活质量.
- 缺乏可靠的临床试验数据来指导在PD中治疗胃肠道功能障碍.
研究的目的:
- 建立共识陈述,用于查,诊断和治疗帕金森病中的胃肠道功能障碍.
- 为临床医生管理PD患者的胃肠道问题提供实用框架.
主要方法:
- 使用了经过修改的Delphi小组方法,涉及运动障碍和胃肠病学专家.
- 进行了五次虚拟的Delphi轮,共识被定义为100%的协议.
- 文献审查为声明草案的制定提供了信息,随后由小组进行讨论,编辑和投票.
主要成果:
- 达成共识的声明是为了查,诊断和治疗帕金森病中常见的胃肠道症状而制定的.
- 建议按消化道的解剖细分进行排列:口腔/食道,胃,小肠和结肠/阳肠.
结论:
- 开发的共识建议为帕金森病中胃肠道功能障碍的诊断和治疗提供了实际框架.
- 这些指导方针旨在改善PD患者胃肠道症状的临床管理.
相关概念视频
Parkinson's Disease: Treatment
263
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263
Parkinson's Disease: Overview
533
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
533
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
309
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
309
Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
Peptic Ulcer Disease IV: Management
89
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
89


